Integra Lifesciences Holdings (IART) Receivables - Other (2017 - 2026)

Integra Lifesciences Holdings has disclosed Receivables - Other across 10 years of filings, most recently posting $6.7 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $6.7 million, up 30.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.7 million (up 30.13% YoY), and the FY2025 annual result was $6.8 million, up 11.36% from the prior year.
• Receivables - Other came in at $6.7 million for Q1 2026 at Integra Lifesciences Holdings, down from $6.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $12.2 million in Q1 2022 to a low of $3.5 million in Q2 2025.
• The 5-year median for Receivables - Other is $7.5 million (2024), against an average of $7.9 million.
• Across the five-year window, Receivables - Other soared 87.98% in 2022 and plunged 47.29% in 2025, its largest moves.
• Integra Lifesciences Holdings' Receivables - Other stood at $10.1 million in 2022, then retreated by 8.78% to $9.2 million in 2023, then slumped by 33.43% to $6.1 million in 2024, then grew by 11.36% to $6.8 million in 2025, then fell by 2.75% to $6.7 million in 2026.
• The last three Receivables - Other figures came in at $6.7 million (Q1 2026), $6.8 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.